Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors
Summary
"Jake Simson, Ph.D., Partner at RA Capital Management, added, "We are proud to support Convergent and believe its radioantibody technology is an exciting approach to radiopharmaceuticals that will have significant implications for patients. A key functional feature of CONV01- is that once bound to PSMA, it becomes internalized, delivering its powerful radioactive payload directly into prostate cancer cells while minimizing damage to surrounding healthy tissue. OrbiMeds team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets. For more information, please visit www.racap.com.About InvusFounded in 1985 and with principal offices in New York, Paris and Hong Kong, The Invus Group is an evergreen investment platform with over USD9Bn of assets under management. Examples include Moderna, BioNTech, Scholar Rock, Seer, Morphic, Generation Bio, Thrive Earlier Detection, Erasca, ElevateBio, Scorpion Therapeutics, and Schrodinger.